

RESPONSE TO LETTER

Response to “Influence of Diabetes on Antiplatelet Drug Efficacy”

Aleksi Tornio¹,
Colin N.A. Palmer² and
Alex S.F. Doney³

To The Editor: Gong *et al.* in their Letter to the Editor make valuable comments in relation to our study, which, as they correctly point out, included a substantial number of individuals with diabetes. First, they draw attention to the well-documented increased platelet reactivity in patients with diabetes, and a recent study showing increased platelet P2Y₁₂ expression may be contributory. They also highlight a recent fairly small study indicating that in stroke patients the *CYP2C19* loss-of-function allele had a reduced impact on clopidogrel response in individuals with higher glycosylated albumin levels independent of diabetes status. Such observations imply reduced efficacy of clopidogrel in this patient population. Indeed, a further study indicates impaired P2Y₁₂ inhibition by clopidogrel in individuals with diabetes is largely mediated by its reduced metabolism.¹ Second, they allude to studies indicating that obese subjects and smokers also have a prothrombotic state and that in smokers this may also be associated with increased platelet P2Y₁₂. Smokers, however, may have an increased clopidogrel responsiveness² through induction of *CYP2C19*, although more recent work has indicated that the impact of smoking on

clopidogrel responsiveness is abrogated when accounting for hemoglobin levels.³

Our study comprised a bioresource linked to electronic medical records. In essence, we conducted a Mendelian-randomized prospective observational study of the clinical impact of *CYP2C19* loss-of-function genotype in a population of individuals who had all redeemed prescriptions for clopidogrel following hospitalization for an arterial thrombo-occlusive event. As a consequence, we are not able to directly compare the overall efficacy of clopidogrel therapy with a comparator arm to investigate the impact of diabetes and related features. However, it is possible to exploit *CYP2C19* genotype as a genetic instrument to probe the extent to which these features modify antiplatelet response. Our overall study comprised 72% individuals with diabetes and 77% of the outcome events occurred in this group. While we found that diabetes, obesity, smoking, and recent elevated glycosylated hemoglobin were, as expected, significantly associated with increased risk, we did not find any evidence of an interaction with the *CYP2C19* genotype. While we probably do not have adequate power in our current study to formally avoid a type II error, a meta-analysis of clinical trials also found no substantial effect of either diabetes or obesity on clopidogrel efficacy.⁴ Our bioresource is currently expanding with the Scottish-wide GoSHARE study (www.goshare.org.uk). As a consequence, we anticipate the ability to explore these interesting and highly clinically relevant aspects in the future.

CONFLICT OF INTEREST

The authors declared no conflict of interest.

FUNDING

The GoDARTS Bioresource has been funded by a wide range of sources of many years. The present study was unfunded.

© 2018 The Authors Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics

This is an open access article under the terms of the Creative Commons Attribution NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

1. Angiolillo, D.J. *et al.* Impaired responsiveness to the platelet P2Y₁₂ receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. *J. Am. Coll. Cardiol.* **64**, 1005–1014 (2014).
2. Zhao, Z.-G. *et al.* The impact of smoking on clinical efficacy and pharmacodynamic effects of clopidogrel: a systematic review and meta-analysis. *Heart* **100**, 192–199 (2014).
3. Kim, Y.G. *et al.* Cigarette smoking does not enhance clopidogrel responsiveness after adjusting VerifyNow P2Y₁₂ reaction unit for the influence of hemoglobin level. *JACC Cardiovasc. Interv.* **9**, 1680–1690 (2016).
4. Zaccardi, F., Pitocco, D., Willeit, P. & Laukkanen, J.A. Efficacy and safety of P2Y₁₂ inhibitors according to diabetes, age, gender, body mass index and body weight: systematic review and meta-analyses of randomized clinical trials. *Atherosclerosis* **240**, 439–445 (2015).

¹Department of Clinical Pharmacology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; ²Pat MacPherson Centre for Pharmacogenetics and Pharmacogenomics, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK; ³Medicines Monitoring Unit, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK. Correspondence: A. Doney (a.doney@dundee.ac.uk)

Received 15 December 2017; accepted 17 December 2017; Advance online publication 30 December 2017. doi:10.1002/cpt.1002